Toggle light / dark theme

Neurological conditions or injuries that result in the inability to communicate can be devastating. Patients with such speech loss often rely on alternative communication devices that use brain–computer interfaces (BCIs) or nonverbal head or eye movements to control a cursor to spell out words. While these systems can enhance quality-of-life, they can only produce around 5–10 words per minute, far slower than the natural rate of human speech.

Researchers from the University of California San Francisco today published details of a neural decoder that can transform brain activity into intelligible synthesized speech at the rate of a fluent speaker (Nature 10.1038/s41586-019‑1119-1).

“It has been a longstanding goal of our lab to create technology to restore communication for patients with severe speech disabilities,” explains neurosurgeon Edward Chang. “We want to create technologies that can generate synthesized speech directly from human brain activity. This study provides a proof-of-principle that this is possible.”

A 3D-Bioplotter® was employed to 3D print (3DP) a humic acid-polyquaternium 10 (HA-PQ10) controlled release fixed dose combination (FDC) tablet comprising of the anti-HIV-1 drugs, efavirenz (EFV), tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC).

Chemical interactions, surface morphology and mechanical strength of the FDC were ascertained. In vitro drug release studies were conducted in biorelevant media followed by in vivo study in the large white pigs, in comparison with a market formulation, Atripla®. In vitro-in vivo correlation of results was undertaken.

EFV, TDF and FTC were successfully entrapped in the 24-layered rectangular prism-shaped 3DP FDC with a loading of ∼12.5 mg/6.3 mg/4 mg of EFV/TDF/FTC respectively per printed layer. Hydrogen bonding between the EFV/TDF/FTC and HA-PQ10 was detected which was indicative of possible drug solubility enhancement. The overall surface of the tablet exhibited a fibrilla structure and the 90° inner pattern was determined to be optimal for 3DP of the FDC. In vitro and in vivo d rug release profiles from the 3DP FDC demonstrated that intestinal-targeted and controlled drug release was achieved.

The new technology enables the printing of personalized medications out of hydrogel objects, producing complex structures which can expand, change shape and activate on a delayed schedule. By prescribing personalized medicines, doctors will be able to accurately tailor the exposure and dosage levels for individual patients.

“We now have the technology to replace standard or traditional formulations. The population is getting older so we need to think of solutions,” said Benny.

“We can now think about combining drugs together into one drug instead of ten, to adjust the kinetics of drugs and improve patient compliance in drug administration.”

“Finally, Artifical [sic] Intelligence that will make you wonder which one of you is real,” reads one of Kapur’s recent tweets, with another urging CES visitors to stop by the NEON corner to learn more about “an Artificial Intelligence being as your best friend.”

Not Bixby

One thing Samsung will say about NEON is that it is not related to the company’s AI-powered digital assistant Bixby.

Americans today spend more on pharmaceuticals per capita than anyone else in the world, and more than one in five say they have trouble affording their prescription drugs. But they might not know about the alternative pathways to medicine. VICE’s Hamilton Morris explores the world of clandestine chemists, DIY bio hackers, and grey markets to see if a more democratized medicinal future is indeed possible.

Check out VICE News for more: http://vicenews.com

Follow VICE News here:
Facebook: https://www.facebook.com/vicenews
Twitter: https://twitter.com/vicenews
Tumblr: http://vicenews.tumblr.com/
Instagram: http://instagram.com/vicenews
More videos from the VICE network: https://www.fb.com/vicevideo

#VICEonHBO